Between 10% and 25% of chronic lymphocytic leukemia (CLL) patients have episodes of autoimmune hemolytic anemia (AIHA) during the course of their disease. The anti-erythrocyte autoantibodies in most cases are polyclonal and express a different heavy chain isotype than the malignant clone, indicating that they are secreted by normal autoreactive B lymphocytes. To further investigate the pathogenesis of the AlHA in CLL, we analyzed the Ig heavy (HI chain variable region genes expressed by leukemic cells from CLL patients with and without AIHA. Two V, genes were preferentially expressed by the leukemic cells in the CLL cases with AlHA and were present in 9 of the 12 investigated cases. The 51plIDP-10 gene was expressed in 5 of these cases and
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HRONIC LYMPHOCYTIC leukemia (CLL) results
C from an accumulation of morphologically small mature B lymphocytes that usually express the CD5 antigen and low levels of membrane IgM.'*2 Characteristic features of CLL are the frequent occurrence of hypogammaglobulinemia and the development of autoantibodies mainly directed against hematopoietic cells.
Autoimmune hemolytic anemia (AMA) occurs in approximately 10% to 25% of CLL patients at some time during the course of the d i~e a s e .~.~ Although the pathogenic autoantibodies occasionally may be produced by the malignant Bcell clone:.6 in most cases the autoantibodies appear to be made by remnant normal B lymphocyte^.'^^ This view is supported by the observation that the antibodies eluted from the red blood cells (RBC) are typically "warm-reactive" polyclonal IgG antibodies that display activity against monomorphic antigens of the rhesus system. On the other hand, the antibodies produced by the CLL cells are usually IgM and are always monoclonal. Experiments with SCID mice reconstituted with peripheral blood lymphocytes from a CLL patient have also suggested that the anti-RBC antibodies are not related to the malignant c10ne.~ A large proportion of these animals developed human IgG anti-RBC autoantibodies that were of polyclonal origin.
Collectively, these data have suggested that the anti-erythrocyte autoantibodies in CLL occur as a consequence of progressive dilution or inhibition of nonneoplastic B or T lymphocytes whose role is to antagonize the autoreactive Bcell clones.*." This model, however, does not provide an explanation for the much higher frequency of AIHA in CLL versus other hematologic malignancies and the lack of correlation between the circulating levels of pathogenic anti-RBC autoantibodies and the duration and severity of the underlying lymphoproliferative disease. An alternative possibility is that the Ig produced by the leukemic cells contributes to the development of AIHA either by being directly involved in RBC destruction or by inducing some of the regulatory abnormalities that lead to the production of pathogenic anti-RBC autoantibodies. To address this issue, we have investigated if there is any bias in the Ig VH region repertoire of CLL patients with AIHA, which could indicate a direct involvement of the CLL clone in the pathogenesis of the hemolytic anemia.
was absent in the control group of 12 consecutive CLL cases without AIHA, whereas the DP-50 gene was present in 4 CLL-AIHA cases and only once in the control CLL group. A strikingly similar H-chain CDR3 region that contained a single reading frame of the DXP4 DH gene segment, an N-encoded proline at the DH/JH boundary, and a tyrosine-rich region encoded by the J,,6 gene segment was observed in four CLL-AIHA cases. The preferential expression of two VH gene segments and a particular CDR3 region by the leukemic cells of patients with AlHA suggests that the antibodies produced by the CLL cells are directly involved in the pathogenesis of the hemolytic anemia.
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MATERIALS AND METHODS

Patients.
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation from 12 CLL patients with direct antiglobulin test (DAT) positive warm AIHA (8 from Macedonia, 2 from Italy, and 2 from the United States) and from 12 consecutive CLL patients that were consistently DAT negative throughout their disease (four from Macedonia and eight from Italy). The diagnosis in all patients was established according to the criteria of the International Workshop on Chronic Lymphocytic Leukemia" and all patients were followed for at least 4 years before the blood sampling. Informed consent was obtained in all cases.
Total cellular RNA was isolated by the procedure of Chomczynski and Sacchi." One microgram of RNA was reverse transcribed (RT) using oligo-dT and the GeneAmp RNAPCR kit (Perkin Elmer Cetus, Norwalk, CT), following the procedure recommended by the manufacturer. The entire RT sample was next subjected to 35 cycles of PCR with 50 pmol of V, and C p specific oligonucleotide primers. The Cp primer p l (5' GTCCTGTGCGAGGCAGCCAA 3') was from the first exon of the heavy chain constant p gene (codons 139 to 145). and was used either with hFWl (5' AGGTGCAGCTGGA(T)GG(C)AGTC(G)- 
RESULTS
Cloning and sequencing of VH genes. The gene segments encoding the heavy chain variable regions of the CLL Igs were amplified by RTPCR from the 12 patients with AIHA and from the 12 DAT-negative controls using a C p primer and either a degenerate primer from FW1 (homologous to published gene segments from the vH1, vH3, vH4, and VHS families) or an equimolar mixture of six family specific primers from the VH leader exon. Six clones were sequenced from each patient and the obtained sequences were always identical. Either direct sequencing or IgM gene fingerprintingI6 was also performed to confirm that these sequences belonged to the malignant clones. The sequences of the VH gene segments from the 24 CLL patients are shown in Fig  1. Four different VH gene segments were identified in the CLL-AIHA group (Fig 1A) . The CLL cells in five patients (HA-1, HA-2, HA-3, HA-5, and HA-9) expressed the VH1 family gene 51pl in germline configuration. The VH genes in four other cases were identical or highly homologous to the vH3 family member DP-50 (HA-4, HA-7, HA-8, and HA-RI). The remaining three CLL-AIHA cases expressed VH genes identical to the v H 3 family member DP-47 (HA-6 and HA-VG) or the VH1 family member DP-25 (HA-IO). The VH sequences in the control CLL group were homologous or identical to nine different VH genes that belonged to the vH4 family (VH4.21 in CL-P and CL-G, VH 4.1 1 in CG-6, and vH4.18 in CG-2), VH3 family (DP-29 in CG-1 and CG-7, DP-35 in GP-4 and CL-D, DP-47 in GP-3, and DP-SO in CLJ) and VH1 family (DP-8 in GP-I and DP-15 in CLO) (Fig 1B) . Only three of these sequences were in germline configuration, whereas the others shared 87% to 99.3% nucleotide sequence homology with published VH gene sequences. Although we cannot exclude that some of these VH gene segments belong to unknown members a n d or polymorphic variants of previously described members of the v H l , vH3, and VH4 gene families, the overall distribution of replacement and silent mutations with a high R/S ratio in CDRl and CDR2 (4.23) and a low R/S ratio in FWI, FW2, and FW3 (0.9) is strongly indicative of somatic mutation and selection. This is further supported by the fact that most of these sequences also contained mutations in the JH gene segments, whereas no mutations were present in the J H gene segments that were associated with germ-line VH genes.
Biased DH gene segment usage was also seen in the CLL-AIHA group, with preferential expression of DXP family members (CLL-AIHA: 7/12 patients, control CLL: 1/12 patients, P = ,009) (Fig 2) . Interestingly, 4 VH domains (patients HAI, HA2, HAS, and HAS) contained a strikingly similar CDR3 region characterized by a DXP4 encoded DFWSGY motif, an Nnucleotide encoded proline, and a J H~ encoded stretch of tyrosines (Fig 2A) . This CDR3 region was associated with the 51pl gene in three cases and the DP-SO gene in one case. A similar CDR3 region containing SGY and the JH6-encoded tyrosines was present in patient HA-10. The JH6 gene segment was preferentially expressed in the CLL patients with hemolytic anemia (7 of 12 cases), whereas D H and JH gene usage appeared random in the control CLL group (Fig 2B) .
Analysis of the DH and J H gene segments.
DISCUSSION
In a recent review of VH gene usage in CLL, Schroeder and Dighiero" showed that the B-CLL clones express a diverse VH gene repertoire. Out of the approximately 50 known germline VH genes, at least 27 were present among the 75 analyzed CLL sequences. At the same time this analysis showed that four VH gene segments ( 5 1~1 , VH4.21, vH4.18, and vH25l) are overrepresented in the CLL VH repertoire, accounting for approximately 50% of the CLL VH domains. This apparent skewing in VH gene segment use and the finding that CLL cells frequently produce polyreactive autoantibodies suggests that the malignant clones in CLL are selected by self-antigens that are preferentially recognized by VH domains encoded by particular gene segm e n t~'~. '~ In the case of the VH4.21 and vH251 genes this conclusion is further supported by the frequent finding of somatic mutations indicative of an antigen driven res p o n~e , '~. '~ as was also observed in a subset of our patients, and by the association of the VH4.21 gene segment with autoantibodies that react with the erythrocyte I/i blood-group antigens .20. 2 
'
We now show that the antibodies produced by the leukemic cells from CLL patients with AIHA are preferentially encoded by the S l p l and DP-SO VH genes. These two VH genes were found in 9 of the 12 CLL-AIHA H-chain sequences, and only once in the control group of CLL patients that had not developed AIHA before the sampling. Chisquare analysis showed a significant correlation between the expression of these VH genes and the occurrence of AIHA ( P < .001), indicating that the S l p l and DP-50 genes have been selected because of particular binding specificities that can contribute to the development of AIHA.
The 51pl gene was present in approximately 12% of the CLL VH sequences from the survey of Schroeder and Dighiero.I7 An even higher frequency of 18% has been reported by the group of Kipps, which investigated S l p l usage in a similar number of CLL cases.'* Taken together, these two studies suggest that the expected frequency of S l p l in CLL is approximately 1S%, which is significantly lower than the frequency we observed in the CLL-AIHA patients (42%, P For personal use only. on October 23, 2017. by guest www.bloodjournal.org From ""-cm1""-
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"""""""""""""""""""."""""""""""""""""""""""" Fig 1 (cont'dl. = .019). A significant correlation between VH gene usage and AIHA was also observed for the DP-50 gene, which was not present among the 75 surveyed sequences from reference 17, but accounted for 33% of the CLL-AIHA sequences ( P < ,001). Interestingly, this VH gene has also been found in 5 of 14 investigated human monoclonal anti-Rh(D) antibodies, indicating that it is also overrepresented in the human anti-Rh(D) re~ponse.'~ The VH domains in four of the CLL-AIHA patients contained a strikingly similar CDR3 region that contained a DFWSGYXP motif (where X corresponds to L or Y) encoded by a single reading frame of the DXP4 gene segment and N-nucleotides from the DH-JH junction (Fig 2A) . This motif was followed by a long stretch of tyrosines encoded by the JH6 gene segment. A similar incomplete motif (SGY) was encoded by the DK1 gene in patient CLL130 and was also associated with the JH6 segment. Although at present we cannot conclude that the Igs containing these conserved structures will bind the same antigen(s), this assumption is not unlikely considering recent findings that autoreactivity of CLL antibodies might be a selected specificity determined by the association of certain VH genes and CDR3 regions. 24325 A similar restriction of the antibody repertoire has been observed in the autoimmune response to RBC antigens in the New Zealand Black inbred strain of autoimmune mice. This strain is considered a mouse model of human CLL since it is characterized by pauciclonal proliferations of CD5' B cells that occur during aging and by frequent occurrence of AIHA.26 The anti-erythr.:cyte antibodies in this strain are directed mainly against antigens that are exposed on the 
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GAT ATG GCC TTG ACT TC G GTG GTA GCT CGC CTA l T T GGG AGG TI ...........................msb....................... For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From surface of intact mouse RBC, such as the erythrocyte band 3 protein. These antibodies are polyclonal, are usually IgG, and are encoded by a variety of VH gene segments that have undergone somatic mutation.27 However, a subset of the antierythrocyte antibodies react only with RBC antigens that become exposed after treatment with proteolytic enzymes such as bromelain. Interestingly, these antibodies are produced by CD5+ B cells and are encoded by only two nonmutated VH gene segments (VH11 and vH12), which are overrepresented in the VH repertoire of mouse CD5+ B cells, but are infrequently expressed by conventional mouse B ~e l l s .~* .~~
The function of these antibromelain treated RBC autoantibodies is still unknown, but a role in the clearance of senescent erythrocytes has been ~uggested.~'
The antibodies produced by the CLL cells could have a similar specificity and could promote the binding of RBCs, sensitized with polyclonal IgG antibodies, to the Fc receptors on macrophages. In a parallel study we have found that a subset of CLL cells produces secretory y-chain transcripts, which in two of the CLL-AIHA patients were predominantly of the y2 and y3 H-chain isotypes (D.G.E., M.I., F.D.B., and O.R.B., manuscript in preparation). Antibodies of the IgG3 subclass seem to play an important role in the initial adherence of sensitized erythrocytes to macrophages because of their greatest affinity for the F c~R I I I .~ Alternatively, the CLL antibodies might not bind directly to RBC antigens, but could represent second antibodies that bind to the Fc portion of the anti-RBC antibodies. Our initial experiments with a recombinant Fv antibody that corresponds to the CLL Ig of patient HA2 show low-affinity reactivity against a number of self antigens including human IgG. Finally, the CLL antibodies could have antiidiotypic activity and could stimulate normal autoreactive B cells to produce anti-RBC antibodies. Antiidiotypic IgG antibodies that crossreact with some anti-Rh(D) antibodies have been detected in eluates from sensitized RBCs and have been implicated in the pathogenesis of A I H A .~~
In conclusion, we have shown that the Ig VH domains expressed by the leukemic cells from CLL patients with AIHA are preferentially encoded by the 51pl and DP-50 VH gene segments in association with a particular CDR3 region. Further studies should determine whether this information can also be used as a prognostic factor to define a subset of CLL patients at an increased risk to develop autoimmune hemolytic anemia.
NOTE ADDED IN PROOF
We have more recently determined the rearranged VH gene sequence in three additional CLL patients with AIHA. The 51pl VH gene encoded the CLL Ig in two of these cases, which raised the frequency of 51pl gene rearrangements in CLL-AIHA to 47% (7/15 cases).
